A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors

Ocular Imaging for Monitoring of Ocular Tumor Disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07449195

Enrollment

Registered

2026-03-04

Start date

2026-02-27

Completion date

2028-02-27

Last updated

2026-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Tumor

Keywords

Ocular Tumors, 25-314, Memorial Sloan Kettering Cancer Center

Brief summary

The purpose of this study is to compare two devices used for optical coherence tomography (OCT). OCT is a noninvasive imaging (scanning) method that uses reflected light to create pictures of the back of the eye, and doctors can use OCT to detect and monitor different types of cancer

Interventions

DIAGNOSTIC_TESTIntalight Dream OCT

This is a next-generation swept-source device that has a faster imaging speed and higher sensitivity than the previous generation of frequency-domain OCT devices, which serve as the current standard of care devices.

DIAGNOSTIC_TESTHeidelberg Spectralis OCT

This is the standard of care for optical imaging.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥18 years. * At least 1 eye that has an intraocular or ocular surface tumor. * The presence of a natural crystalline lens or intraocular lens. * Pupils that can dilate up to at least 3 mm in the study eyes. * The absence of opaque natural crystalline lenses or the presence of any ocular disease that prevents the view of the retina for imaging. * Patients must be able to fixate on the imaging target. * Patients must be able to sit still for a period of time (approximately 2 minutes).

Exclusion criteria

* Does not meet ALL of the above conditions

Design outcomes

Primary

Measure	Time frame	Description
Image quality for participants	Up to 1 year	Evaluated by next-generation swept-source OCT versus standard OCT for imaging of the eye and any relevant ocular tumors.
Field of view for participants	Up to 1 year	Evaluated by next-generation swept-source OCT versus standard OCT for imaging of the eye and any relevant ocular tumors.

Countries

United States

Contacts

CONTACTJasmine Francis, MD

francij1@mskcc.org212-639-7266

CONTACTDavid Abramson, MD

abramsod@mskcc.org212-639-7232

PRINCIPAL_INVESTIGATORJasmine Francis, MD

Memorial Sloan Kettering Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 14, 2026